Innovive Pharmaceuticals Announces Additional Data Presentations at,American Association for Cancer Research Annual Meeting ( NEW YORK--(BUSINESS WIRE)--Apr 12 2007...)

HOME >> MEDICINE >> TECHNOLOGY

Innovive Pharmaceuticals Announces Additional Data Presentations at,American Association for Cancer Research Annual Meeting

NEW YORK--(BUSINESS WIRE)--Apr 12, 2007 - INNOVIVE Pharmaceuticals, Inc. (OTCBB:IVPH) today announced that data from preclinical studies of INNO-406, a potent oral dual Bcr-Abl and Lyn-kinase inhibitor for Gleevec-resistant or treatment-intolerant chronic myelogenous leukemia, will be presented at the American Association for Cancer Research Annual Meeting. The meeting takes place April 14-18, 2007 at the Los Angeles Convention Center in Los Angeles, California.

Information related to the presentations is as follows: -0-

Presentation Title:    "The dual ABL/SRC inhibitors dasatinib,

                       SKI-606, and INNO-406 are potent inhibitors of

                       T cell acute lymphoblastic leukemia cell lines

                       expressing the NUP214-ABL1 fusion kinase"


Abstract Number:       1825


Session:               Poster Section 7, Clinical Research 8, Poster

                       Board #11


Session Date and Time: Monday, April 16, 2007, 8:00 a.m. - 12:00 p.m.


Location:              Exhibit Hall, Los Angeles Convention Center





Presentation Title:    "Cell death and autophagy induced by INNO-406,

                       a novel Bcr-Abl inhibitor, in Philadelphia

                       leukemias"


Abstract Number:       2768


Session:               Poster Section 10, Cellular and Molecular

                       Biology 31, Poster Board #17


Session Date and Time: Monday, April 16, 2007, 1:00 p.m. - 5:00 p.m.


Location:              Exhibit Hall, Los Angeles Convention Center

-0-

Presentation Title:    "Overcoming imatinib resistance using Src

                       inhibitor CGP76030, Abl inhibitor nilotinib,

                       and Abl/Lyn inhibitor INNO-406 in newly

                       established K562 variants with bcr-abl gene

                       amplification"


Abstract Number:       3246


Session:               Poster Section 29, Experimental and Molecular

                     
'"/>




Page: 1 2 
Related medicine technology :

1. Innovive Pharmaceuticals to Present Interim Data from Phase I Study
of INNO-406 at the American Society of Clinical Oncology Annual
Meeting
2. Innovive Pharmaceuticals Announces Preclinical Data from INNO-206
Oncology Program
3. Innovive Pharmaceuticals Announces Data from Oncology Drug Programs
to be Presented at American Association for Cancer Research Annual
Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird
Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II
Study of its Factor Xa Inhibitor at the XXI Congress of the
International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for
Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging
Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin
Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin
Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials &
Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III
Data with Rifamycin MMX in Infectious Diarrhea

Post Your Comments:

( NEW YORK--(BUSINESS WIRE)--Apr 12 2007...)Innovive Pharmaceuticals Announces Additional Data Presentations at,American Association for Cancer Research Annual Meeting,Health